Pipeline
Learn more about our R&D pipeline and ongoing trials below
Development Programs – Solid Tumor
Drug
Indication
Phase 1
Phase 2
Phase 3
BGB-24714 (SMAC Mimetic) +/- Chemotherapy
Advanced Solid Tumors
BGB-3245
(BRAF inhibitor)
Advanced solid tumors with BRAF mutations
BGB-B167 (CEA-4-1BB bispecific antibody) +/- Tislelizumab
(anti-PD-1)
Advanced solid tumors
BGB-B167 +/- Tislelizumab
Advanced or metastatic solid tumors
BGB-A445 (anti-OX40) +/- Tislelizumab
Select advanced solid tumors
BGB-A445 + Tislelizumab
Select advanced solid tumors
LBL-007 (anti-LAG-3) +/- Tislelizumab + Bevacizumab + Capecitabine*
Maintenance in unresectable or metastatic MSS/mismatch repair proficient CRC
Lifirafenib (RAF inhibitor) + Mirdametinib
(MEK inhibitor)
Advanced solid tumors
Ociperlimab (anti-TIGIT) + Tislelizumab
1L PD-L1 high advanced NSCLC
2L PD-L1+ advanced ESCC
2L + cervical cancer
Advanced solid tumors
Ociperlimab + Tislelizumab + BAT1706
(anti-VEGF)
1L HCC
Ociperlimab + Tislelizumab + Chemotherapy
1L NSCLC
Ociperlimab + Tislelizumab + Concurrent Chemoradiotherapy
Previously untreated, stage III unresectable NSCLC
Previously untreated LS-SCLC
Pamiparib
(PARP 1/2 inhibitor)
2L/3L maintenance platinum-sensitive OC
Advanced OC and TNBC
Pamiparib + Temozolomide
Advanced solid tumors
Tislelizumab
1L HCC
2L/3L NSCLC
1L MSI-H or dMMR CRC
Previously treated advanced MSI-high or dMMR solid tumors
Tislelizumab +/- Surzebiclimab (anti-TIM-3) +/- LBL-007*
Advanced solid tumors
Tislelizumab +/- Ociperlimab +/- LBL-007*
Resectable stage II/IIIA NSCLC
Tislelizumab +/- BGB-A445 +/- LBL-007 +/- Chemotherapy*
1L advanced, unresectable, or metastatic NSCLC
Tislelizumab + BGB-10188
(PI3Kδ inhibitor)
Advanced solid tumors
Tislelizumab + BGB-15025
(HPK1 inhibitor)
Advanced solid tumors
Tislelizumab + Chemoradiotherapy
Localized ESCC
Tislelizumab + Chemotherapy/ Chemoradiotherapy
Resectable ESCC
Tislelizumab + Chemotherapy
1L advanced ESCC
1L GC/GEJC
Resectable stage II or IIIA NSCLC
1L advanced nasopharyngeal cancer
1L squamous NSCLC
1L non-squamous NSCLC
1L advanced UBC
1L ES-SCLC
Tislelizumab + DKN-01 (anti-DKK1) + Chemotherapy*
1L/2L GC/GEJC
Tislelizumab + Fruquintinib
(VEGFR inhibitor)
Advanced GC/GEJC, CRC, and NSCLC
Advanced triple negative BC, EC, and CRC
Tislelizumab + Lenvatinib
(VEGFR kinase inhibitor)
1L HCC
Advanced solid tumors
Tislelizumab + Sitravatinib
(multikinase inhibitor)
Advanced NSCLC after anti-PD-(L)1 therapy
Advanced GC/GEJC/HCC
HCC post resection
Advanced ESCC after anti-PD-(L)1 therapy
Tislelizumab + Surufatinib
(VEGFR, FGFR, CSF-1R inhibitor)
Advanced solid tumors
Zanidatamab
(anti-HER2 bi-specific antibody)
2L+ HER2+ BTC
Zanidatamab + Chemotherapy +/- Tislelizumab
1L HER2+ BC and 1L HER2+ GC/GEJC
1L HER2+ advanced/metastatic GC/EC
Australia, S. Korea, US
Australia, China
Australia, US
China
China, S. Korea
China, S.Korea, Thailand
China, Thailand
Coming Soon
United States
Worldwide
BC, breast cancer; BRAF, B-Raf proto-oncogene; BRCA+, breast cancer susceptibility gene-positive; BTC, biliary tract cancer; dMMR, deficient mismatch repair; ESCC, esophageal squamous cell carcinoma; ES-SCLC; extensive-stage small cell lung cancer; GBM, glioblastoma multiforme; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocelluar carcinoma; HER2-, human epidermal growth factor receptor-2–negative; HER2+, human epidermal growth factor receptor-2–positive; MSI, microsatellite instability; NSCLC, non-small cell lung cancer; OC, ovarian cancer; R/R, recurrent/refractory; SCLC, small lung cell cancer; TNBC, triple-negative breast cancer; UBC, urothelial bladder cancer.
Development Programs – Hematology
Drug
Indication
Phase 1
Phase 2
Phase 3
Tislelizumab
(anti-PD-1)
R/R cHL
R/R cHL
BGB-10188 +/- Zanubrutinib
B-cell malignancies
BGB-11417 monotherapy
(Bcl-2 inhibitor)
B-cell malignancies
R/R CLL/SLL
R/R MCL
BGB-11417 + Azacitidine +/- Posaconazole
Myeloid malignancies
BGB-11417 + Dexamethasone +/- Carfilzomib
R/R multiple myeloma with t(11;14)
BGB-11417 monotherapy + zanubrutinib
B-cell malignancies
BGB-16673
(BTK-targeted CDAC)
B-cell malignancies
B-cell malignancies
Ociperlimab (anti-TIGIT) +/- Tislelizumab or Rituximab
R/R DLBCL
Zandelisib +/- Zanubrutinib or Rituximab*
CLL/SLL and B-cell NHL
Zanubrutinib
R/R DLBCL with CD79B
Previously treated B-cell malignancies
B-cell malignancies
Bioavailability of zanubrutinib tablets vs capsules in healthy volunteers
Zanubrutinib + Lenalidomide +/- Rituximab
R/R DLBCL
Zanubrutinib + Obinutuzumab
R/R FL
Zanubrutinib + Rituximab
1L MCL
R/R MZL
Zanubrutinib +/- Venetoclax†
1L CLL/SLL
Australia, China
Australia, US
China
Japan
Switzerland, US
United States
Worldwide
* In collaboration with MEI Pharma
† This combination is being studied in the third cohort of NCT03336333
CDAC chimeric degradation activating compound; B-cell NHL, B-cell non-Hodgkins lymphoma; cHL, classical Hodgkin lymphoma; CLL, chronic lymphotic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; GCB, germinal center B cell-like; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; NK, natural killer; R/R, recurrent/refractory; SLL, small lymphocytic lymphoma; WM, Waldenstrӧm macroglobulinemia.
Interactive Clinical Pipeline
Videos
PARPI Mechanism of Action
Anti-PD-1 Mechanism of Action
BTKI Mechanism of Action
Anti-TIGIT Mechanism of Action
